

Adda Nathalie  
Form 4  
July 19, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Adda Nathalie

2. Issuer Name **and** Ticker or Trading  
Symbol  
ENANTA PHARMACEUTICALS  
INC [ENTA]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)  
C/O ENANTA  
PHARMACEUTICALS, INC., 500  
ARSENAL STREET  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
07/18/2018

\_\_\_\_ Director \_\_\_\_ 10% Owner  
\_\_\_\_X\_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)  
Sr. VP & Chief Medical Officer

WATERTOWN, MA 02472

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_\_\_\_X\_\_\_\_ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/18/2018		M	2,955	A \$ 43.46	6,555	D
Common Stock	07/18/2018		S <sup>(1)</sup>	2,075	D \$ 123.7155	4,480	D
Common Stock	07/18/2018		S <sup>(1)</sup>	445	D \$ 124.2008	4,035	D
Common	07/18/2018		S <sup>(1)</sup>	1,621	D \$	2,414	D

# Edgar Filing: Adda Nathalie - Form 4

Stock					125.6029			
					(4)			
					\$			
Common Stock	07/18/2018	S(1)	904	D	126.3953	1,510	D	
					(5)			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title
Stock Option (Right to Buy)	\$ 43.46	07/18/2018		M	2,955	(6)	06/29/2025	Common Stock
								Amount or Number of Shares
								2,955

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director 10% Owner Officer Other

Adda Nathalie  
C/O ENANTA PHARMACEUTICALS, INC.  
500 ARSENAL STREET  
WATERTOWN, MA 02472

Sr. VP & Chief Medical Officer

## Signatures

/s/ Nathaniel S. Gardiner as  
attorney-in-fact

07/19/2018

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.
  - (2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$122.925 to \$123.87, inclusive.
  - (3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$123.95 to \$124.48, inclusive.
  - (4) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$125.09 to \$126.07, inclusive.
  - (5) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$126.12 to \$126.90, inclusive.
- The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or
- (6) will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.